Ekta Perera, MD
Allergy & Immunology · Houston, TXNPI 1083025902
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $46,885 of the $74,666 with a category attached, or 62.8%. AstraZeneca accounts for 78.1% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $63,390, more than ten times the $1,236 reported in 2019. Among allergy & immunology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 273 payments — averaging $273.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$58K
- Sanofi$12K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$898
- Takeda Pharmaceuticals U.S.A., Inc.$418
- CSL Behring$323
- plus $2K from 22 others
What the payments were for
- Consulting fees$11,37415%
- Speaking & faculty fees$46,88563%
- Travel & lodging$6,2438%
- Food & beverage$9,89013%
- Education$2740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 111 | $58,328 |
| Sanofi | 27 | $11,597 |
| GSK | 34 | $1,007 |
| Regeneron Healthcare Solutions, Inc. | 25 | $898 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $418 |
| CSL Behring | 9 | $323 |
| Pharming Healthcare, Inc. | 5 | $314 |
| Novartis | 13 | $248 |
| Grifols USA, LLC | 11 | $243 |
| Johnson & Johnson(2 entities) | 3 | $187 |
| Octapharma USA, Inc. | 1 | $155 |
| Teva Pharmaceuticals USA, Inc. | 1 | $135 |
| Genentech, Inc. | 1 | $128 |
| Genentech USA, Inc. | 1 | $123 |
| Shire North American Group Inc | 1 | $121 |
| Actelion Pharmaceuticals US, Inc. | 3 | $92 |
| Sanofi-aventis U.S. LLC | 1 | $77 |
| Pfizer | 2 | $46 |
| Blueprint Medicines Corporation | 1 | $35 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $33 |
| Greer Laboratories, Inc. | 1 | $31 |
| Lilly USA, LLC | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Harmony Biosciences LLC | 1 | $20 |
| Jubilant Hollisterstier LLC | 1 | $20 |
| Phadia US Inc. | 1 | $15 |
| Insmed, Inc. | 1 | $14 |
| GC Biopharma USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$74,666 in reported general payments places this provider in the 90th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine Hcl | 20 | $599 |
| Fluticasone Propionate | 29 | $396 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $275 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Houston
- Juan ZambranoHouston$146K
- Joud HajjarHouston$52K
- Sara AnvariHouston$35K
- Sarah NicholasHouston$32K
- Julie PatelHouston$24K
- Rama YerramsettiHouston$24K
- Christopher CollacoHouston$21K
- Mahboobeh MahdaviniaHouston$20K
- Joseph DiazSan Antonio$1.1M
- Richard WassermanDallas$452K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.